Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Warren · SciRah

Researcher profile · Semantic Scholar

M. Warren

Share profile

M. Warren — researcher profile on SciRah

h-index: 16
Works: 37
Citations: 8,165

Most-cited papers

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
S. Marso, S. Bain, A. Consoli, F. Eliaschewitz +11 more
2016New England Journal of Medicine5,447 citations Open access
Semantic Scholar
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
M. Husain, Andreas L. Birkenfeld, M. Donsmark, K. Dungan +11 more
2019New England Journal of Medicine1,447 citations Open access
Semantic Scholar
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
T. Pieber, B. Bode, A. Mertens, Young Min Cho +90 more
2019The Lancet Diabetes and Endocrinology241 citations Open access
Semantic Scholar
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial
W. Lane, T. Bailey, G. Gerety, J. Gumprecht +4 more
2017Journal of the American Medical Association (JAMA)197 citations Open access
Semantic Scholar
Long‐term treatment with the dipeptidyl peptidase‐4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52‐week efficacy and safety study
M. Nowicki, I. Rychlík, H. Haller, M. Warren +3 more
2011International journal of clinical practice148 citations Open access
Semantic Scholar
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
A. Bo, S. Atkin, G. Charpentier, M. Warren +4 more
2018Diabetes, obesity and metabolism142 citations Open access
Semantic Scholar
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
M. Nowicki, I. Rychlík, H. Haller, M. Warren +2 more
2011Diabetes, obesity and metabolism133 citations Open access
Semantic Scholar
Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1‐5 trials
M. Warren, L. Chaykin, D. E. Trachtenbarg, Gurudutt Nayak +2 more
2018Diabetes, obesity and metabolism65 citations Open access
Semantic Scholar
Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism
M. Mannstadt, B. Clarke, J. Bilezikian, H. Bone +10 more
2019Journal of Clinical Endocrinology and Metabolism60 citations Open access
Semantic Scholar
Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.
M. Warren, M. Conway, L. Klaff, J. Rosenstock +1 more
2004Diabetes Research and Clinical Practice60 citations
Semantic Scholar
Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials
C. Sorli, M. Warren, D. Oyer, H. Mersebach +2 more
2013Drugs & Aging51 citations Open access
Semantic Scholar
Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO‐Pump‐2
M. Warren, B. Bode, Ik-Cho Jang, Rong Liu +6 more
2020Diabetes, obesity and metabolism37 citations Open access
Semantic Scholar
Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
E. Jódar, M. M. Michelsen, W. Polonsky, R. Réa +6 more
2020Diabetes, obesity and metabolism34 citations Open access
Semantic Scholar
Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare).
B. Bode, L. Chaykin, A. Sussman, M. Warren +3 more
2014Endocrine Practice31 citations
Semantic Scholar
EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES.
C. Wysham, R. Hood, M. Warren, Tao Wang +2 more
2016Endocrine Practice23 citations
Semantic Scholar
Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin
M. Warren, L. Chaykin, S. Jabbour, M. Sheikh-Ali +3 more
2017Clinical Diabetes18 citations Open access
Semantic Scholar
Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients
Ofri Mosenzon, Eden M. Miller, M. Warren
2020Postgraduate medicine14 citations Open access
Semantic Scholar
Semaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5
Lawrence A Leiter, G. Charpentier, L. Chaykin, T. Garvey +4 more
20179 citations
Semantic Scholar
932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program
V. Aroda, R. Bauer, C. Hertz, E. Montanya +3 more
2020Diabetes7 citations
Semantic Scholar
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism
N. Watts, J. Bilezikian, H. Bone, B. Clarke +10 more
2023Journal of the Endocrine Society6 citations Open access
Semantic Scholar
Five-year efficacy and safety of recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) for the treatment of adults with chronic hypoparathyroidism: analysis from the open-label race study
B. Clarke, D. Shoback, J. Bilezikian, H. Bone +10 more
20183 citations
Semantic Scholar
Recombinant human parathyroid hormone (rhPTH[1-84], parathyroid hormone rDNA) improves hypercalciuria in patients with hypoparathyroidism: 3-year analysis from RACE study
B. Clarke, T. Vokes, J. Bilezikian, H. Bone +10 more
20173 citations
Semantic Scholar
Three-year safety and efficacy data for recombinant human parathyroid hormone, rhPTH(1-84), in the treatment of adults with hypoparathyroidism: the RACE study
B. Clarke, M. Mannstadt, T. Vokes, J. Rothman +6 more
20153 citations
Semantic Scholar
Long-term effects of recombinant human parathyroid hormone, rhPTH(1-84), on bone remodelling in patients with hypoparathyroidism: 3-year data from the open-label RACE study
M. Levine, J. Bilezikian, B. Clarke, M. Mannstadt +4 more
20153 citations
Semantic Scholar
57 - Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program
S. Pedersen, V. Aroda, R. Bauer, C. Hertz +3 more
20202 citations
Semantic Scholar
OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study
J. Bilezikian, H. Bone, B. Clarke, D. Denham +10 more
2019Journal of the Endocrine Society2 citations Open access
Semantic Scholar
Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes
M. Warren, M. Brod, J. Håkan-Bloch, T. Sparre +1 more
2019Current Medical Research and Opinion2 citations Open access
Semantic Scholar
Abstract #806367: The Efficacy of Once-Weekly Subcutaneous Semaglutide is Comparable in Subjects with Type 2 Diabetes Aged < 65 Years and ≥ 65 Years: A Post Hoc Analysis of Sustain 1-5 and 7-10
M. Warren
20201 citations
Semantic Scholar
Author response for "Semaglutide improves health-related quality of life vs placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)"
E. Jódar, M. Michelsen, W. Polonsky, R. Réa +6 more
20201 citations
Semantic Scholar
Recombinant human parathyroid hormone 1-84 for the treatment of adults with chronic hypoparathyroidism: Six-year safety and efficacy results of the RACE study
J. Bilezikian, H. Bone, B. Clarke, D. Denham +11 more
2019Endocrine Abstracts1 citations
Semantic Scholar
Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme
S. Jacob, S. Bain, R. Réa, M. Warren +3 more
2018Diabetologie und Stoffwechsel1 citations Open access
Semantic Scholar
Review for "Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg in patients age < 65 and ≥ 65 years: post hoc analysis of the AWARD‐11 trial"
M. Warren
20210 citations Open access
Semantic Scholar
61 - Comparable Efficacy of Once-Weekly Subcutaneous Semaglutide in Subjects With Type 2 Diabetes Aged <65 and ≥65 Years: SUSTAIN 1–5 and 7–10 Posthoc Analysis
Akshay B. Jain, M. Warren, C. Hindsberger, J. Lawson +3 more
20200 citations
Semantic Scholar
91 - Efficacy and Safety of Semaglutide in Elderly Subjects with Type 2 Diabetes: Posthoc Analysis of SUSTAIN 7
S. Stafford, V. Aroda, D. Sugimoto, D. E. Trachtenbarg +4 more
2019Canadian Journal of Diabetes0 citations
Semantic Scholar
Efficacy and safety of semaglutide in elderly subjects with type 2 diabetes: a post hoc analysis of the SUSTAIN 7 trial
W. Schmidt, V. Aroda, D. Sugimoto, D. E. Trachtenbarg +4 more
2019Diabetologie und Stoffwechsel0 citations
Semantic Scholar
Elderly Patients Experience a Lower Rate of Nocturnal Hypoglycemia with Insulin Degludec Than with Insulin Glargine: A Meta-Analysis of Phase 3a Trials
C. Sorli, M. Warren, H. Mersebach, T. Johansen +2 more
20130 citations Open access
Semantic Scholar
Options for Intensification with Biphasic Insulins in Patients with Type 2 Diabetes Not Achieving Glycemic Control
M. Warren
20130 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Mannstadt×8
Invite
M. Mannstadt — researcher profile on SciRah
B. Clarke×8
Invite
B. Clarke — researcher profile on SciRah
J. Bilezikian×8
Invite
J. Bilezikian — researcher profile on SciRah
M. Levine×8
Invite
M. Levine — researcher profile on SciRah

×8

Invite

D. Shoback — researcher profile on SciRah

Invite

T. Vokes — researcher profile on SciRah

Invite

D. Denham — researcher profile on SciRah

Invite

J. Rothman — researcher profile on SciRah

Invite

H. Bone — researcher profile on SciRah

Invite

M. Peacock — researcher profile on SciRah

Invite

N. Watts — researcher profile on SciRah

Invite

L. Chaykin — researcher profile on SciRah